Evidence map›Paper›PMID 42258055›Full record

Trial reportClinical and experimental nephrology2026

Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease.

Chie Saito, Kaori Mase, Shun Ishibashi, Takuya Harada, Ryoya Tsunoda, Toshiaki Usui, Tatsuya Simizu, Kei Nagai, Reiko Ohkubo, Naoki Morito and 4 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chie SaitoDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Kaori MaseDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Shun IshibashiDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Takuya HaradaDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Ryoya TsunodaDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Toshiaki UsuiDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Tatsuya SimizuDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Kei NagaiDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Reiko OhkuboDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Naoki MoritoDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Masahiro HagiwaraDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Hirayasu KaiDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Joichi UsuiDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Kunihiro YamagataDepartment of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. k-yamaga@md.tsukuba.ac.jp.ORCID http://orcid.org/0000-0002-7407-0410

Funding

Strategic Promotion of Innovative R and D JPJ012425
6 · The paper itself

Abstract

backgroundCilostazol has antiplatelet and vasodilatory properties and may provide renoprotective and cardiovascular benefits; however, its effects in patients with advanced chronic kidney disease (CKD) remain unclear.

methodsThis prospective pilot study enrolled 12 patients with advanced CKD due to nephrosclerosis (7 men, 5 women; mean age 65.3 ± 11.0 years). Patients were randomly assigned to receive cilostazol 200 mg/day plus aspirin 100 mg/day (Group C, n = 6) or aspirin 100 mg/day alone (Group A, n = 6). Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured using inulin and para-aminohippuric acid clearance at baseline and after 1 year. Renal outcomes and complications were evaluated, followed by long-term observation until initiation of renal replacement therapy (RRT).

resultsBaseline GFR and RPF were comparable between groups. After 1 year, GFR increased in 4 of 6 patients in Group C but declined in all patients in Group A. Mean GFR decreased significantly in Group A but not in Group C. Although estimated GFR declined in both groups, the annual rate of decline was significantly slower in Group C than in Group A (- 2.72 vs. - 3.84 mL/min/1.73 m

conclusionCilostazol may slow short-term renal function decline and offer long-term cardiovascular protection in patients with advanced CKD. Further studies are needed to determine its role in preventing long-term renal deterioration.

Indexed as

CilostazolGlomerular Filtration RateKidneyPlatelet Aggregation InhibitorsRenal CirculationRenal Insufficiency, ChronicTetrazolesAgedAspirinFemaleHumansMaleMiddle AgedNephrosclerosisPilot ProjectsPrognosisAspirinCilostazolPlatelet Aggregation InhibitorsTetrazolesCilostazolEstimated GFRGlomerular filtration rateLong-term effectRenal replacement therapy initiation

Identifiers

PMID42258055
PMCPMC13582073

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.